论文部分内容阅读
目的 利用溴隐亭逆转人肝癌化疗耐药性。方法 78例未经任何治疗的原发性肝癌患者先后行2次99mTc 甲氧基异丁基异腈(MIBI)单光子发射计算机断层显像(SPECT)检测,经外周静脉注射2 0mCi99mTc MIBI后15和12 0min行平面显像半定量分析肿物部位的摄取比值(UR)第1次SPECT检测后口服溴隐亭2 .5mg/次,3次/d ,连续3d后进行第2次SPECT检测,两次检测结果进行对照比较。结果 68例肝癌患者99mTc MIBISPECT肿瘤无MIBI摄取,10例患者99mTc MIBISPECT肿瘤部位有MIBI摄取。经溴隐亭治疗后所有肿瘤MIBI排空者均出现99mTc MIBI浓聚。结论 溴隐亭作为一种新型逆转剂可有效逆转临床肝癌患者的多药耐药性
Objective To use bromocriptine to reverse chemoresistance in human hepatocellular carcinoma. Methods 78 patients with primary liver cancer without any treatment were followed by 99mTc methoxy-isobutyl isonitrile (MIBI) single photon emission computed tomography (SPECT), peripheral vein injection of 20mCi99mTc MIBI after 15 and 12 0min line semi-quantitative analysis of tumor imaging of the tumor site uptake ratio (UR) after the first SPECT oral bromocriptine 2. 5mg / time, 3 times / d, after 3 consecutive days of the second SPECT test twice Test results for comparison. Results There was no MIBI uptake in 99mTc MIBISPECT tumors in 68 HCC patients and MIBI uptake in 99mTc MIBISPECT tumor sites in 10 patients. 99mTc MIBI accumulation occurred in all tumor MIBI-evacuated patients after bromocriptine treatment. Conclusion Bromocriptine can effectively reverse multidrug resistance in patients with hepatocellular carcinoma as a new reversal agent